Patent intelligence · US
US 9132174
Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
Patent details — US 9132174
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 15, 2015
- Expiration
- Sep 10, 2035
- Applicant
- Anchored RSK3 Inhibitors, LLC
- Claims
- 32
- CPC classes
- A61K, A61K31/519, A61K31/7048, A61K31/713
Quick answer
US 9132174 (Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)) is held by Anchored RSK3 Inhibitors, LLC. Status: granted. Granted Sep 15, 2015. Expires Sep 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Anchored RSK3 Inhibitors, LLC
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K31/519, A61K31/7048, A61K31/713, A61K38/005, A61K38/1709
More from Anchored RSK3 Inhibitors, LLC
Related pharmaceutical patents in our USPTO index.
-
US 11931402
Compositions for treating heart disease by inhibiting the action of mAKAP-β
granted -
US 11229679
Compositions for treating heart disease by inhibiting the action of mAKAPβ
granted -
US 10617737
Compositions for treating heart disease by inhibiting the action of mAKAP-β
granted -
US 9937228
Treatment of myocardial infarction by inhibiting the action of mAKAPβ
granted
Frequently asked questions
What is US patent 9132174?
US 9132174 (Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)) is held by Anchored RSK3 Inhibitors, LLC. Status: granted. Granted Sep 15, 2015. Expires Sep 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9132174?
Anchored RSK3 Inhibitors, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 9132174 expire?
Our index shows an expiration date of Sep 10, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.